Tiemann Investment Advisors LLC Makes New $258,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Tiemann Investment Advisors LLC acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,962 shares of the company’s stock, valued at approximately $258,000.

A number of other hedge funds also recently made changes to their positions in the business. Pacer Advisors Inc. raised its stake in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after acquiring an additional 1,347,775 shares during the period. Boston Trust Walden Corp lifted its stake in shares of Amphastar Pharmaceuticals by 81.4% during the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock worth $36,347,000 after buying an additional 439,281 shares during the last quarter. Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $10,804,000. Portolan Capital Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 201.1% during the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock worth $15,906,000 after buying an additional 218,901 shares during the period. Finally, Weiss Asset Management LP acquired a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at about $4,967,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Up 1.7 %

Shares of AMPH opened at $28.81 on Monday. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12 month low of $26.98 and a 12 month high of $53.96. The firm’s 50 day moving average is $33.71 and its 200-day moving average is $41.93. The stock has a market capitalization of $1.37 billion, a PE ratio of 9.60, a P/E/G ratio of 2.19 and a beta of 0.77.

Insider Buying and Selling

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now owns 118,469 shares of the company’s stock, valued at $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on AMPH. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.